PMID- 25133707
OWN - NLM
STAT- MEDLINE
DCOM- 20141009
LR  - 20221207
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 38
IP  - 9
DP  - 2014 Sep
TI  - Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of 
      the 2013 ASCO/CAP guideline update.
PG  - 1227-34
LID - 10.1097/PAS.0000000000000268 [doi]
AB  - Her2 gene amplification and protein overexpression are important factors in 
      predicting clinical sensitivity to anti-HER2 monoclonal antibody therapy in 
      breast, gastric, or gastro-esophageal junction cancer patients. The purpose of 
      this study was to evaluate the HER2 status in the mucinous epithelial ovarian 
      cancer (EOC). Adopting the 2013 American Society for Clinical Oncology and the 
      College of American Pathologists guideline update for HER2 testing, 49 tissue 
      microarray samples of mucinous EOC were analyzed by immunohistochemistry (IHC) 
      and fluorescence in situ hybridization (FISH) tests. The prevalence of HER2 
      positivity in Asian mucinous EOC was 9 of 49 Asian women (18.37%). The overall 
      concordance was 100% between IHC and FISH results. Her2 gene copies before 
      chromosome-17 correction increased significantly in a stepwise order through the 
      negative, equivocal, and positive IHC result categories (P<0.001), as did the 
      Her2 gene copies after chromosome-17 correction (P<0.001). Of the Taiwanese 
      cohort (n=21), HER2 heterogeneity was 4.76% (1/21) in all but 14.26% (1/7) in 
      HER2-positive cancer. In conclusion, we demonstrated that the prevalence of HER2 
      positivity in both Asian and white women was comparable; complete HER2 
      concordance existed between IHC and FISH tests for the Her2 gene copies per tumor 
      cell either before or after correction of chromosome-17, and this can be applied 
      as a potentially valuable tool to analyze the HER2 status. Polysomy-17 was absent 
      under the CEP17 cutoff >/=3. The existence of HER2 heterogeneity can be discerned 
      in certain HER2-expressed primary mucinous EOC in Taiwanese women.
FAU - Chao, Wan-Ru
AU  - Chao WR
AD  - *Institute of Medicine, Chung-Shan Medical University Departments of daggerPathology 
       parallelObstetrics and Gynecology, School of Medicine, Chung-Shan Medical University and 
      Chung-Shan Medical University Hospital  paragraph signPathology, School of Medicine, Chung-Shan 
      Medical University and Chung-Shan Medical University Hospital double daggerDepartment of 
      Statistics and Informatics Science, Providence University  section signDepartment of 
      Pathology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
FAU - Lee, Ming-Yung
AU  - Lee MY
FAU - Lin, Wea-Lung
AU  - Lin WL
FAU - Koo, Chiew-Loon
AU  - Koo CL
FAU - Sheu, Gwo-Tarng
AU  - Sheu GT
FAU - Han, Chih-Ping
AU  - Han CP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Asian People
MH  - *Biomarkers, Tumor/analysis/genetics
MH  - Biopsy
MH  - Carcinoma, Ovarian Epithelial
MH  - Chromosomes, Human, Pair 17
MH  - Female
MH  - *Gene Amplification
MH  - Genetic Predisposition to Disease
MH  - Guideline Adherence
MH  - Humans
MH  - Immunohistochemistry/*standards
MH  - In Situ Hybridization, Fluorescence/*standards
MH  - *Neoplasms, Cystic, Mucinous, and Serous/chemistry/ethnology/genetics/pathology
MH  - *Neoplasms, Glandular and Epithelial/chemistry/ethnology/genetics/pathology
MH  - *Ovarian Neoplasms/chemistry/ethnology/genetics/pathology
MH  - Phenotype
MH  - Practice Guidelines as Topic
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - *Receptor, ErbB-2/analysis/genetics
MH  - Societies, Medical
MH  - Taiwan/epidemiology
MH  - White People
EDAT- 2014/08/19 06:00
MHDA- 2014/10/10 06:00
CRDT- 2014/08/19 06:00
PHST- 2014/08/19 06:00 [entrez]
PHST- 2014/08/19 06:00 [pubmed]
PHST- 2014/10/10 06:00 [medline]
AID - 00000478-201409000-00008 [pii]
AID - 10.1097/PAS.0000000000000268 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2014 Sep;38(9):1227-34. doi: 10.1097/PAS.0000000000000268.